Zhengzhou Univ. CYP2E1 compound 10

Zhengzhou Univ. CYP2E1 compound 10: sourced facts only. name: "Through virtual screening, synthesis, and optimization, we identified compound 10 as a favorable selective and potent CYP2E1 inhibitor, with a Kd of 7.02 μM, an IC50 of 1.64 μM, and a Ki of 0.897 μM." [PMID:40318482]; target: "Through virtual screening, synthesis, and optimization, we identified compound 10 as a favorable selective and potent CYP2E1 inhibitor, with a Kd of 7.02 μM, an IC50 of 1.64 μM, and a Ki of 0.897 μM." [PMID:40318482]; developer: "Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China." [PMID:40318482]; modality: "Overall, our study identified a selective and potent small molecule CYP2E1 inhibitor 10, which may not only serve as a candidate compound for the treatment of SAP but also lay the groundwork for future drug development of anti-inflammatory agents." [PMID:40318482]; stage: "Notably, treatment with 10 significantly reduced mortality, inflammation, and oxidative stress in mouse models of severe acute pancreatitis (SAP) induced by Caerulein combined with lipopolysaccharide (LPS) or l-Arginine." [PMID:40318482]